Gene Solutions and Pangea Laboratory Collaborate on Cancer Detection

Gene Solutions and Pangea Laboratory have announced a strategic partnership aimed at enhancing the verification and clinical validation of liquid biopsy assays in the United States. The collaboration, revealed on January 21, 2026, will focus on cancer detection, profiling, and monitoring using advanced technologies.

Under the terms of the agreement, Gene Solutions, a global biotechnology firm headquartered in Singapore, will provide standard operating procedures (SOPs), funding, and technical assistance from its CAP-accredited Next Generation Sequencing (NGS) laboratories located in Singapore and Vietnam. Pangea Laboratory, recognized for its expertise in validation platforms for Laboratory Developed Tests (LDTs) and accredited by CLIA and CAP, will manage all analytical and clinical validation processes at its facilities in Irvine, California.

Combining Expertise for Cancer Care

The partnership aims to streamline the U.S. readiness for Gene Solutions’ AI-driven multi-omics liquid biopsy technologies, ensuring they meet CLIA and CAP quality standards. Dr. Hoa Giang, Co-founder and Chief Data Science Officer of Gene Solutions, emphasized the significance of this collaboration, stating, “Through our collaboration with Pangea, we’re combining Gene Solutions’ AI-driven multi-omics innovation with world-class U.S. validation expertise.”

The initial phase of the collaboration will prioritize Gene Solutions’ two flagship NGS tests, which are designed to improve cancer detection and monitoring. John Moore, CEO of Pangea Laboratory, expressed enthusiasm for the venture, noting that Pangea is eager to support the introduction of SPOT-MAS and K-4CARE to the U.S. market. These tests are intended to complement Pangea’s existing Bladder CARETM assay, which focuses on early bladder cancer detection.

About the Companies Involved

Founded in 2014, Pangea Laboratory specializes in high complexity testing and validation services for innovative assays, including NGS and molecular diagnostics. The company has established a reputation for its rigorous validation processes tailored to meet the needs of innovative LDTs. More information about Pangea Laboratory can be found on their website at https://pangealab.com.

Gene Solutions has been at the forefront of biotechnology since its inception, dedicated to making advanced genomic solutions accessible and affordable. The company leverages multi-omics, NGS, and artificial intelligence to provide a range of services, including multicancer early detection with its SPOT-MAS test and comprehensive tumor profiling through K-TRACK and K-4CARE. Since 2017, Gene Solutions has conducted millions of genetic tests globally. For further details, visit www.genesolutions.com.

As the partnership progresses, both companies are committed to enhancing cancer care through innovative technologies and validated testing processes. This collaboration reflects a growing trend in the healthcare industry to integrate advanced diagnostics with clinical validation, ultimately benefiting clinicians and patients alike.